1. |
Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer[J].Oncogene, 2002; 21(14)∶2245.
|
2. |
趙 新, 張培瑞, 俞祥海, 等. 腺病毒介導TIMP2基因轉染抑制大鼠腹主動脈細胞外基質降解的實驗研究 [J]. 中國普外基礎與臨床雜志, 2007; 14(3)∶276.
|
3. |
Jia L, Zhou H, Wang S, et al. Deglycosylation of CD147 down-regulates Matrix Metalloproteinase-11 expression and the adhesive capability of murine hepatocarcinoma cell HcaF in vitro [J]. IUBMB Life, 2006; 58(4)∶209.
|
4. |
Sambrook J, Fritsch EF, Maniatis T Eds. Molecular cloning: A Laboratory Manual[M]. 2nd ed. New York: CHS press, 1989.
|
5. |
伍志堅, 吳小兵, 曹 暉, 等. 一種高效的重組腺伴隨病毒載體生產系統 [J]. 中國科學(C輯), 2001; 31(5)∶423.
|
6. |
吳小兵, 董小巖, 伍志堅, 等. 一種快速高效分離和純化腺病毒伴隨病毒載體的方法 [J]. 科學通報, 2000; 45(19)∶2071.
|
7. |
Debelak D, Fisher J, Iuliano S, et al. Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2[J]. J Chromatogr B Biomed Sci Appl, 2000; 740(2)∶195.
|
8. |
Matsumoto E, Nakatsukasa H, Nouso K, et al. Increased levels of tissue inhibitor of metalloproteinase-1 in human hepatocellular carcinoma [J]. Liver Int, 2004; 24(4)∶379.
|
9. |
Monahan PE, Samulski RJ, Tazelaar J, et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia [J]. Gene Ther, 1998; 5(1)∶40.
|
10. |
Rabinowitz JE, Samulski RJ. Building a better vector: the manipulation of AAV virions[J]. Virology, 2000; 278(2)∶30111 Santat L, Paz H, Wong C, et al. Recombinant AAV2 transduction of primitive human hematopoietic stem cells capable of serial engraftment in immune-deficient mice [J]. Proc Natl Acad Sci USA, 2005; 102(31)∶11053.
|
11. |
劉自明, 嚴律南, 李馨筱. 包載攜有HSVTK基因腺病毒PLG微球的制備 [J]. 中國普外基礎與臨床雜志, 2007; 14(4)∶399.
|
12. |
張明滿, 李德華, 茍興華, 等. 靶向肝癌細胞的重組腺相關病毒載體的構建 [J]. 中國普外基礎與臨床雜志, 2005; 12(2)∶142.
|
13. |
Hermonat PL, Quirk JG, Bishop BM, et al. The packaging capacity of adeno-associated virus (AAV) and the potential for wild-type-plus AAV gene therapy vectors [J]. FEBS Lett, 1997; 407(1)∶78.
|
14. |
Phillips MI. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension [J]. Hypertension, 1997; 29(1 Pt 2)∶177.
|
15. |
Grimm D, Kern A, Rittner K, et al. Novel tools for production and purification of recombinant adenoassociated virus vectors [J]. Hum Gene Ther, 1998; 9(18)∶2745.
|
16. |
Zolotukhin S, Byrne BJ, Mason E, et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield [J]. Gene Ther, 1999; 6(6)∶973.
|
17. |
Clark KR, Liu X, McGrath JP, et al. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses [J]. Hum Gene Ther, 1999; 10(6)∶1031.
|
18. |
夏 冬, 徐 亮, 萬禮儀, 等. 重組腺病毒介導hTIMP1對人肝癌細胞系體外增殖的影響 [J]. 中國普外基礎與臨床雜志, 2007; 14(4)∶409.
|
19. |
伍志堅, 吳小兵, 侯云德. 系列腺病毒伴隨病毒載體的構建及表達β-半乳糖苷酶的研究 [J]. 病毒學報, 2000; 16(1)∶1.
|